Pharmaceuticals
Nanoform Commenced Relative Bioavailability Study of Nanotechnology-Enhanced Enzalutamide
HELSINKI, Jan. 5, 2024 /PRNewswire/ -- Nanoform Finland Plc ("Nanoform"), the medicine performance enhancing company, today announced it had completed the First Subject First Visit (FSFV) in a trial to evaluate the relative bioavailability of its nanocrystalline enabled alternative; to an amorpho...
2024-01-05 14:35
2313
Menarini Group and Insilico Medicine Enter Global Exclusive License Agreement for Novel KAT6 Inhibitor for Potential Breast Cancer Treatment and Other Oncology Indications
* KAT6 is an emerging target in hormone sensitive breast tumors and other cancers. Overexpression of KAT6A/B correlates with poor clinical outcomes in patients with ER+/HER2- breast cancer – the most common subtype. * The molecule has demonstrated strong preclinical activity. Insilico present...
2024-01-05 00:19
4258
Avenzo Therapeutics Announces Global License of AVZO-021 (ARTS-021), a Potentially Best-in-Class Clinical Stage CDK2 Inhibitor from Allorion Therapeutics
- AVZO-021 demonstrated a potential best-in-class preclinical potency, selectivity and pharmacokinetic profile - AVZO-021 is currently in an ongoing U.S.-based Phase 1 clinical study in advanced solid tumors - Avenzo also obtains an exclusive option to an additional preclinical program planned ...
2024-01-04 21:02
2525
Ribo partners with Boehringer Ingelheim to develop new treatments for people with liver diseases
INGELHEIM, Germany, MÖLNDAL, Sweden and KUNSHAN, China, Jan. 3, 2024 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. and Ribocure AB (Ribo) today announced a collaboration with Boehringer Ingelheim to develop novel treatments for nonalcoholic or metabolic dysfunction-associated steatohepatitis...
2024-01-03 19:37
4274
Belief BioMed Successfully Completed Dosing of First Subject in the Registrational Clinical Trial for Hemophilia A
SHANGHAI, Jan. 3, 2024 /PRNewswire/ -- Belief BioMed Group (BBM), an industry-leading biotech company focusing on innovative gene therapies, announced the completion of first subject dosing in its registrational clinical trial (CTR20233400) of BBM-H803, a gene therapy for hemophilia A, independen...
2024-01-03 18:10
6577
Sciwind Biosciences Announces Positive Topline Results from Phase 3 Clinical Trial of Ecnoglutide (XW003), a Long-acting cAMP Signaling Biased GLP-1 Analog, in Adult Patients with Type 2 Diabetes in China
* Study participants receiving 0.6 and 1.2 mg ecnoglutide once weekly for 24 weeks achieved HbA1c reductions of 1.96 and 2.43% from baseline, respectively, compared to 0.87 % for placebo * In the 1.2 mg ecnoglutide cohort, 76.1% of participants achieved HbA1c ≤ 6.5% and 35.2% achieved HbA1c< ...
2024-01-03 10:00
4123
Allorion Therapeutics Announces Exclusive Option and Global License Agreement for Novel Preclinical-Stage EGFR L858R Allosteric Inhibitor Program with AstraZeneca
NATICK, Mass., Jan. 2, 2024 /PRNewswire/ -- Allorion Therapeutics ("Allorion"), a US andChina-based biotechnology company that focuses on the discovery of new small molecule drugs for treating cancer and autoimmune diseases, has entered into an exclusive option and global license agreement with A...
2024-01-02 22:00
2994
Gannex Announces Positive Interim Results from 52-Week Phase II Clinical Trial of Once-Daily ASC41 Tablet in Patients with Biopsy-Confirmed Non-alcoholic Steatohepatitis
--Up to 68.2% mean relative reduction in liver fat content from baseline in biopsy-confirmed non-alcoholic steatohepatitis (NASH) patients receiving 12-week treatment of ASC41 tablet --At Week 12, up to 93.3% patients achieved at least a 30% relative reduction in liver fat content from baseline ...
2024-01-02 20:06
4594
Innovent Dosed First Participant in Phase 3 Clinical Study (GLORY-2) of Mazdutide (IBI362) Higher Dose 9 mg in Chinese Adults with Obesity
ROCKVILLE, Md. and SUZHOU, China, Jan. 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and o...
2024-01-02 08:00
11754
ANAESTHESIOLOGIST HERO, DOCTOR'S QUICK THINKING SAVES CYCLIST'S LIFE DURING LEKAS NIGHT RIDE 2023
Off-duty doctor's decisive action and collaboration with fellow physician-cyclists lead to a successful resuscitation and life-saving measures. SELANGOR, MALAYSIA, Dec. 29, 2023 /PRNewswire/ -- In an extraordinary display of quick thinking and medical expertise, Dr. Shahridan Bin Mohd Fathil, an ...
2023-12-29 17:20
4035
Positive Results In The Interim Analysis Of The Clinical Trial Of Recbio's Novel Adjuvanted Recombinant Shingles Vaccine REC610 In The Philippines
TAIZHOU, China, Dec. 29, 2023 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group") is pleased to announce that the novel adjuvanted recombinant shingles vaccine REC610 independently developed by the Company has recently achieved positive...
2023-12-29 12:33
4951
Clover Announces Positive Phase Ⅰ Results for SCB-219M for Treatment of Chemotherapy-Induced Thrombocytopenia (CIT)
--All CIT patients maintained platelet counts >75 x 109/L at 1-week following chemotherapy plus a single dose of SCB-219M, with durable responses through at least 3-weeks-- --Durable efficacy and PK profile expected to support convenient dosing interval of ≥2-weeks, compared to daily or weekly d...
2023-12-29 07:30
4376
HANSIZHUANG Sets Sail in Indonesia Market
* The 1st China anti-PD-1 monoclonal antibody successfully approved in Southeast Asia - * The 1st overseas approval of HANSIZHUANG, highlighting another major milestone of Henlius' global strategy after HANQUYOU - * Along with KGbio and other partners to develop and launch HANSIZHUANG in ov...
2023-12-28 21:51
5695
RemeGen's Pioneering RC88 Receives IND Approval from US FDA for Platinum-Resistant Recurrent Ovarian Cancer Treatment
YANTAI, China, Dec. 28, 2023 /PRNewswire/ -- RemeGen Co. Ltd.
2023-12-28 15:45
3448
Innovent and Xuanzhu Enter into Clinical Trial Collaboration Investigating Combination Therapy of Sintilimab (PD-1 inhibitor) and A Novel ADC Candidate for Advanced Solid Tumors in China
ROCKVILLE, Md. and SUZHOU, China, Dec. 28, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology an...
2023-12-28 08:00
5143
Boan Biotech's Two Innovative Drugs Targeting Claudin 18.2 Granted ODD by FDA
YANTAI, China, Dec. 27, 2023 /PRNewswire/ -- Boan Biotech today announced that two of its Claudin18.2-targeted investigational drugs have been granted the Orphan Drug Designation (ODD) for the treatment of pancreatic cancer by the U.S. Food and Drug Administration (FDA): one is BA1105, an innovat...
2023-12-27 20:50
5076
Seegene obtains ISO45001 certification
SEOUL, South Korea, Dec. 27, 2023 /PRNewswire/ -- Seegene Inc. (KQ096530), a leading South Korean company providing a total solution for PCR molecular diagnostics, announced that it has achieved an ISO45001 certification on December 27. The Occupational Health and Safety Management System (ISO ...
2023-12-27 20:00
3641
Rx-360® Announces 2024 Board of Directors
PHILADELPHIA, Dec. 27, 2023 /PRNewswire/ -- Rx-360® is pleased to announce its 2024 Board of Directors. As a non-profit, the Board of Directors is positioned to continue driving the Rx-360® mission of pharmaceutical supply chain security, material quality, and patient safety. This announcement fo...
2023-12-27 13:00
4284
Innovent and SanegeneBio Enter Strategic Collaboration to Develop siRNA Drug for the Treatment of Hypertension
ROCKVILLE, Md. and SUZHOU, China, Dec. 27, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology an...
2023-12-27 08:00
5756
Davos Communications Awards - BGI Genomics Inclusive Instagram Strategy Wins Gold Recognition
HONG KONG, Dec. 22, 2023 /PRNewswire/ -- BGI Genomics, the world's leading provider of integrated solutions for precision medicine, is pleased to announce winning Instagram Campaign (Gold) recognition at the Davos Communications Awards held onDecember 12, 2023. Organized by the World Communicati...
2023-12-22 08:19
4408
Week's Top Stories
Most Reposted
Responsible Fintech Institute Appoints Four Executive Fellows and Elevates Distinguished Professor Patrick H. M. Loh to Co-Founder
[Picked up by 279 media titles]
2026-09-29 09:00
ViewSonic Launches VG1457 Dual-Screen Portable Monitor for Productivity Anywhere
[Picked up by 269 media titles]
2026-09-30 10:50
Zenika CTO Adrien Nortain Moves Base to Singapore to Strengthen Technical Leadership in Asia
[Picked up by 267 media titles]
2026-10-01 10:00
Sunway University to Host Asia's First Global Tipping Points Conference 2026
[Picked up by 263 media titles]
2026-09-30 12:11
Southeast Asia's China travel map is widening, Traveloka platform data shows
[Picked up by 260 media titles]
2026-10-05 11:51Most Read
MixVio AI Launches Unified Creative Workspace Across 26 AI Generation Routes
2026-10-02 00:30
23532
